Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Inmaculada Jiménez-Nácher, Elena Alvarez, Judit Morello, Sonia Rodriguez-Nóvoa, Susana de Andrés & Vincent Soriano. (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opinion on Drug Metabolism & Toxicology 7:4, pages 457-477.
Read now
Read now
Articles from other publishers (30)
Yuanlu Shu, Ziwei Deng, Hongqiang Wang, Yi Chen, Lijialong Yuan, Ye Deng, Xiaojun Tu, Xiang Zhao, Zhihua Shi, Minjiang Huang & Chengfeng Qiu. (2021) Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials. AIDS Research and Therapy 18:1.
Crossref
Crossref
Midori Kato‐Maeda, Annie Luetkemeyer & Peter M. Small. 2021. Tuberculosis and Nontuberculous Mycobacterial Infections. Tuberculosis and Nontuberculous Mycobacterial Infections
481
497
.
Saneesh Kumar, Patrick J. Bouic & Bernd Rosenkranz. (2020) In Vitro Assessment of the Interaction Potential of Ocimum basilicum (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism. Frontiers in Pharmacology 11.
Crossref
Crossref
Mutsa Bwakura Dangarembizi, Pearl Samson, Edmund V. Capparelli, Carolyn Bolton Moore, Patrick Jean-Philippe, Stephen A. Spector, Nahida Chakhtoura, Alex Benns, Bonnie Zimmer, Lynette Purdue, Chivon Jackson, Carole Wallis, Jennifer L. Libous & Ellen G. Chadwick. (2019) Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. JAIDS Journal of Acquired Immune Deficiency Syndromes 81:4, pages 473-480.
Crossref
Crossref
Guilherme Suarez‐Kurtz, Eleni Aklillu, Yoshiro Saito & Andrew A. Somogyi. (2019) Conference report: pharmacogenomics in special populations at WCP2018. British Journal of Clinical Pharmacology 85:3, pages 467-475.
Crossref
Crossref
Ethel D. Weld, Alice K. Pau, Gary Maartens & Kelly E. Dooley. 2019. HIV and Tuberculosis. HIV and Tuberculosis
239
267
.
Ethel D. Weld & Kelly E. Dooley. (2018) State-of-the-Art Review of HIV-TB Coinfection in Special Populations. Clinical Pharmacology & Therapeutics 104:6, pages 1098-1109.
Crossref
Crossref
Daniel Atwine, Maryline Bonnet & Anne-Marie Taburet. (2018) Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. British Journal of Clinical Pharmacology 84:8, pages 1641-1658.
Crossref
Crossref
Giorgia Sulis, Silvia Amadasi, Anna Odone, Martina Penazzato & Alberto Matteelli. (2018) Antiretroviral Therapy in HIV-Infected Children With Tuberculosis. Pediatric Infectious Disease Journal 37:5, pages e117-e125.
Crossref
Crossref
Rocsanna Namdar & Charles A. Peloquin. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
221
253
.
Abiy Habtewold, Eleni Aklillu, Eyasu Makonnen, Wondwossen Amogne, Getnet Yimer, Getachew Aderaye, Leif Bertilsson, Joel S. Owen & Jürgen Burhenne. (2016) Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. The Journal of Clinical Pharmacology 56:12, pages 1538-1549.
Crossref
Crossref
Giacomo Maria Paganotti, Gianluca Russo, Martin Sanou Sobze, George Bouting Mayaka, Charles Waithaka Muthoga, Leabaneng Tawe, Axel Martinelli, Rita Romano & Vincenzo Vullo. (2015) CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon. Infection, Genetics and Evolution 35, pages 122-126.
Crossref
Crossref
Abiy Habtewold, Eyasu Makonnen, Wondwossen Amogne, Getnet Yimer, Getachew Aderaye, Leif Bertilsson, Jürgen Burhenne & Eleni Aklillu. (2015) Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics 16:10, pages 1047-1064.
Crossref
Crossref
Hadija H. Semvua, Gibson S. Kibiki, Elton R. Kisanga, Martin J. Boeree, David M. Burger & Rob Aarnoutse. (2015) Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs. Therapeutic Drug Monitoring 37:1, pages 22-32.
Crossref
Crossref
Emile Bienvenu, Michael Ashton & Angela Äbelö. (2015) Influence of <i>CYP</i>2<i>B</i>6 516G > T and Long Term HAART on Population Pharmacokinetics of Efavirenz in Rwandan Adults on HIV and Tuberculosis Cotreatment. Pharmacology & Pharmacy 06:11, pages 533-546.
Crossref
Crossref
Jackson K Mukonzo, Sarah Nanzigu, Paul Waako, Jasper Ogwal-Okeng, Lars L Gustafson & Eleni Aklillu. (2014)
CYP2B6
genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure
. Pharmacogenomics 15:11, pages 1423-1435.
Crossref
Crossref
Hai-Yin Jiang, Min-Na Zhang, Hai-Jun Chen, Ying Yang, Min Deng & Bing Ruan. (2014) Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. International Journal of Infectious Diseases 25, pages 130-135.
Crossref
Crossref
Yasuhiro Horita & Norio Doi. (2014) Comparative Study of the Effects of Antituberculosis Drugs and Antiretroviral Drugs on Cytochrome P450 3A4 and P-Glycoprotein. Antimicrobial Agents and Chemotherapy 58:6, pages 3168-3176.
Crossref
Crossref
Jayakanthan Mannu, Pranitha Jenardhanan & Premendu P. Mathur. (2013) Computational analysis of CYP3A4-mediated metabolism to investigate drug interactions between anti-TB and anti-HIV drugs in HIV/TB co-infection. Medicinal Chemistry Research 23:2, pages 905-917.
Crossref
Crossref
Maryline Bonnet, Nilesh Bhatt, Elisabeth Baudin, Carlota Silva, Christophe Michon, Anne-Marie Taburet, Laura Ciaffi, Agnès Sobry, Rui Bastos, Elizabete Nunes, Christine Rouzioux, Ilesh Jani & Alexandra Calmy. (2013) Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. The Lancet Infectious Diseases 13:4, pages 303-312.
Crossref
Crossref
Anna Turkova, Rachel H. Webb & Hermione Lyall. (2012) When to Start, What to Start and Other Treatment Controversies in Pediatric HIV Infection. Pediatric Drugs 14:6, pages 361-376.
Crossref
Crossref
Anna Turkova, Rachel H. Webb & Hermione Lyall. (2012) When to Start, What to Start and Other Treatment Controversies in Pediatric HIV Infection. Pediatric Drugs 14:6, pages 361-376.
Crossref
Crossref
Shirin Heidari, Lynne M. Mofenson, Charlotte V. Hobbs, Mark F. Cotton, Richard Marlink & Elly Katabira. (2012) Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, pages 161-169.
Crossref
Crossref
Elna van der Ryst, Michael J Palmer & Cloete van Vuuren. 2011. Neglected Diseases and Drug Discovery. Neglected Diseases and Drug Discovery
322
365
.
S. Swaminathan, C. Padmapriyadarsini, P. Venkatesan, G. Narendran, S. Ramesh Kumar, S. Iliayas, P. A. Menon, S. Selvaraju, N. P. Pooranagangadevi, P. K. Bhavani, C. Ponnuraja, M. Dilip & R. Ramachandran. (2011) Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial. Clinical Infectious Diseases 53:7, pages 716-724.
Crossref
Crossref
Luke F. Chen & Donald Kaye. (2011) Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides. Medical Clinics of North America 95:4, pages 819-842.
Crossref
Crossref
B. Ryan Phelps & Natella Rakhmanina. (2011) Antiretroviral Drugs in Pediatric HIV-Infected Patients. Pediatric Drugs 13:3, pages 175-192.
Crossref
Crossref
Michael N. Neely & Natella Y. Rakhmanina. (2011) Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents. Clinical Pharmacokinetics 50:3, pages 143-189.
Crossref
Crossref
Weerawat Manosuthi, Preecha Tantanathip, Sukanya Chimsuntorn, Boonchuay Eampokarap, Supeda Thongyen, Samruay Nilkamhang & Somnuek Sungkanuparph. (2010) Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. International Journal of Infectious Diseases 14:11, pages e1013-e1017.
Crossref
Crossref
Marcos Abdo Arbex, Marília de Castro Lima Varella, Hélio Ribeiro de Siqueira & Fernando Augusto Fiúza de Mello. (2010) Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha. Jornal Brasileiro de Pneumologia 36:5, pages 626-640.
Crossref
Crossref